Pemetrexed Market
- 2026 年市場規模
- USD 2,494.2 Mn
- 2033 年預估規模
- USD 2,907.6 Mn
- 年複合成長率 CAGR
- 2.2%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Pemetrexed Market, By Strength (100 mg ,500 mg), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
報告摘要
Pemetrexed is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. Pemetrexed is a patented drug of Eli Lilly and Company and sold under brand name Alimta. In 2004, Alimta (Pemetrexed injection) was approved by US FDA (Food and Drug Administration) in combination with cisplatin as an initial treatment for patients with malignant pleural mesothelioma. As a single agent for the maintenance treatment of patients with locally advanced or metastatic non squamous (non-small cell lung cancer) NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. It is a single agent for the treatment of patients with recurrent, metastatic non-squamous (non-small cell lung cancer) NSCLC after prior chemotherapy.
Market Dynamics
Launch of generic version of pemetrexed in key region is expected to increase affordability of pemetrexed, which in turn is expected to drive global pemetrexed market growth over the forecast period. For instance, in July 2018, STADAPHARM GmbH, an international pharmaceutical company the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe. The drug is used for treating locally advanced, metastasized and non-small cell lung cancer and is a generic of the product Alimta by Lilly. The launch helped the company in further expansion in pharmaceutical sector.
High prevalence of non-small cell lung cancer and pleural mesothelioma is expected to rise the demand for pemetrexed drive global pemetrexed market growth over the forecast period. For instance, according to the data published by American Society of Clinical Oncology, an oncology organization, in January 2018, in the U.S. around 234,030 adults (121,680 men and 112,350 women) were diagnosed with lung cancer among which non-small cell lung cancer is the most common type of lung cancer, accounting for 80% to 85% of all lung cancer diagnose.
Furthermore, key players in the market are dedicated to expand the indication of its pemetrexed drugs in order to increase its sale and generate high revenues. For instance, in June 2018, Eli Lilly and Company, a U.S.-based pharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for a new indication for ALIMTA (pemetrexed for injection) in combination with carboplatin and KEYTRUDA (pembrolizumab) for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status.
Key features of the study
• This report provides an in-depth analysis of the global pemetrexed market, market size (USD Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2026 – 2033, considering 2025 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global pemetrexed market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include, Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc, Fresenius Kabi USA, Teva Pharmaceuticals USA, Inc, Biocon, Pfizer Inc., Apotex Inc, Dr. Reddy’s Laboratories Ltd, Cadila Pharmaceuticals., Accord Healthcare, Accure Labs Pvt. Ltd, Shanghai Henlius Biotech, Inc., Janssen Global Services, LLC, and Checkpoint Therapeutics, Inc..
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global pemetrexed market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global pemetrexed market.
Market Segmentation
• Strength Insights (Revenue, USD Mn, 2026 - 2033)
o 100mg
o 500mg
• Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Regional Insights (Revenue, USD Mn, 2026 - 2033)
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC Countries
Israel
Rest of Middle East
o Africa
South Africa
North Africa
Central Africa
• Key Players Insights
o Eli Lilly and Company
o Stada Arzneimittel AG
o Eagle Pharmaceuticals, Inc
o Fresenius Kabi USA
o Teva Pharmaceuticals USA, Inc
o Biocon
o Pfizer Inc.
o Apotex Inc
o Reddy’s Laboratories Ltd
o Cadila Pharmaceuticals.
o Accord Healthcare
o Accure Labs Pvt. Ltd
o Shanghai Henlius Biotech, Inc.
o Janssen Global Services, LLC
o Checkpoint Therapeutics, Inc.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
o Market Definition and Scope
o Executive Summary
Market Snapshot, By Strength
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Novel Product Launch/Approval
o Merger-Acquisition Scenario
o PEST Analysis
o Regulatory Scenario
o Reimbursement Scenario
o Epidemiology
4. Global Pemetrexed Market, By Strength, 2026-2033, (USD Mn)
o Overview
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o 100mg
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o 500mg
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
5. Global Pemetrexed Market, By Distribution Channel, 2026-2033, (USD Mn)
o Overview
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Hospital Pharmacies
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Retail Pharmacies
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Online Pharmacies
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
6. Global Pemetrexed Market, By Region, 2026-2033, (USD Mn)
o Introduction
Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, For Region, 2021 - 2033
o North America
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Strength, 2026-2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
Market Size and Forecast, By Country, 2026-2033, (USD Mn)
o U.S.
o Canada
o Latin America
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Strength, 2026-2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
Market Size and Forecast, By Country, 2026-2033, (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Strength, 2026-2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
Market Size and Forecast, By Country, 2026-2033, (USD Mn)
o UK
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Strength, 2026-2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
Market Size and Forecast, By Country, 2026-2033, (USD Mn)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Strength, 2026-2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
Market Size and Forecast, By Country, 2026-2033, (USD Mn)
o GCC Countries
o Israel
o Rest of Middle East
o Africa
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Strength, 2026-2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
Market Size and Forecast, By Country, 2026-2033, (USD Mn)
o North Africa
o Central Africa
o South Africa
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profiles
Eli Lilly and Company
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Stada Arzneimittel AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Eagle Pharmaceuticals, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Fresenius Kabi USA
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Teva Pharmaceuticals USA, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Biocon
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Pfizer Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Apotex Inc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Reddy’s Laboratories Ltd
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Cadila Pharmaceuticals.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Accord Healthcare
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Accure Labs Pvt. Ltd
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Shanghai Henlius Biotech, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Janssen Global Services, LLC,
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Checkpoint Therapeutics, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
8. Section
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們